Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
AbbVie
(NY:
ABBV
)
86.64
USD
+0.20 (+0.23%)
Streaming Delayed Price
/ Updated:
2:38 PM EST, Dec 10, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
4,693,914
Open
86.92
Bid (Size)
86.63 (1)
Ask (Size)
86.64 (3)
Prev. Close
86.44
Today's Range
86.21 - 86.95
52wk Range
62.66 - 92.99
Shares Outstanding
1,586,879,451
Dividend Yield
4.14%
Performance
YTD
-2.91%
-2.91%
1 Month
+1.14%
+1.14%
3 Month
+29.89%
+29.89%
6 Month
+12.59%
+12.59%
1 Year
-1.11%
-1.11%
Top News
More News
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
December 09, 2019
category
Featured News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
December 09, 2019
Financialnewsmedia.com News Commentary
Read More
from
PR Newswire
More News
Read More
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
December 09, 2019
from
GlobeNewswire News Releases
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
December 09, 2019
from
PR Newswire
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Ly
December 08, 2019
from
PR Newswire
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unr
December 07, 2019
from
PR Newswire
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
December 07, 2019
from
PR Newswire
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
December 07, 2019
from
PR Newswire
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
December 06, 2019
from
GlobeNewswire News Releases
5 Stocks Moving On ASH Presentations
December 09, 2019
category
TGTX
,
ASH
,
Trading Ideas
, and 17 more.
from
Benzinga
Drugmakers have spent a record $342 billion on M&A in 2019
December 09, 2019
category
Pharmaceuticals
,
Health/Care
,
MRK
, and 19 more.
from
MarketWatch
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.